Drugs / Tunodafil
Tunodafil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05976503 | Dec 2022 → Mar 2023 | erectile dysfunction | Yangtze River Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07692867 | Apr → Nov 2021 | erectile dysfunction | Yangtze River Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tunodafil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07692867 ↗ |
| Known as | Tunodafilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314444 ↗ |
| Known as | Yonkenafil | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314444 ↗ |
| Modality | Small molecule | — CHEMBL5314444 ↗ |
| Route | Oral | “A single oral dose of Tunodafil Hydrochloride Tablets” NCT05976503 ↗ |